Ira Shivitz, MD
Ophthalmology · Nashville, TNNPI 1881690766
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 397 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AbbVie at 27.1% of the total.
Across 397 payments — averaging $22.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Biotissue Holdings Inc.$923
- Bausch & Lomb, A Division Of Bausch Health US, LLC$711
- Bausch & Lomb Americas Inc.$701
- Johnson & Johnson Vision Care, Inc.$517
- Oyster Point Pharma, Inc.$429
- plus $3K from 21 others
What the payments were for
- Food & beverage$8,992100%
- Gifts$450%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 123 | $2,446 |
| Biotissue Holdings Inc. | 32 | $923 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 44 | $711 |
| Bausch & Lomb Americas Inc. | 38 | $701 |
| Johnson & Johnson Vision Care, Inc. | 5 | $517 |
| Oyster Point Pharma, Inc. | 19 | $429 |
| Glaukos Corporation | 11 | $376 |
| Harrow Eye, LLC | 15 | $350 |
| Eyevance Pharmaceuticals LLC | 19 | $340 |
| Sun Pharmaceutical Industries Inc. | 16 | $328 |
| Alcon | 11 | $322 |
| Tarsus Pharmaceuticals, Inc. | 10 | $304 |
| Thea Pharma Inc. | 10 | $223 |
| Dompe US, Inc. | 7 | $193 |
| Shire North American Group Inc | 10 | $162 |
| Rxsight Inc | 2 | $152 |
| Kala Pharmaceuticals, Inc. | 6 | $120 |
| Akorn, Inc. | 3 | $70 |
| Mallinckrodt Enterprises LLC | 2 | $63 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $61 |
| Aerie Pharmaceuticals, Inc. | 3 | $59 |
| Novartis | 3 | $50 |
| Mallinckrodt Hospital Products Inc. | 2 | $43 |
| ANI Pharmaceuticals, Inc. | 1 | $25 |
| Sanofi | 1 | $24 |
| NEW World Medical,inc. | 1 | $23 |
| Tearlab Corp | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,037 in reported general payments places this provider in the 85th percentile of 323 ophthalmology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 15 | $502,279 |
| RestasisCyclosporine | 63 | $72,131 |
| LumiganBimatoprost | 115 | $57,568 |
| MieboPerfluorohexyloctane/Pf | 64 | $52,260 |
| TyrvayaVarenicline Tartrate | 27 | $20,918 |
| Cyclosporine | 21 | $20,247 |
| CombiganBrimonidine Tartrate/Timolol | 42 | $19,298 |
| RocklatanNetarsudil Mesylat/Latanoprost | 36 | $14,754 |
| Lotemax SmLoteprednol Etabonate | 49 | $13,049 |
| Alphagan PBrimonidine Tartrate | 23 | $10,317 |
| Loteprednol Etabonate | 80 | $10,261 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 24 | $5,537 |
| VyzultaLatanoprostene Bunod | 14 | $5,340 |
| LotemaxLoteprednol Etabonate | 14 | $4,784 |
| Travoprost | 16 | $4,173 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $193 | $502,27915 claims |
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $2,446 | $159,314243 claims |
| Bausch & Lomb Americas Inc.Miebo, Vyzulta | $701 | $57,60078 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Loteprednol Etabonate, Lotemax | $711 | $28,094143 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $429 | $20,91827 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $59 | $14,75436 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 323 ophthalmology providers in Tennessee.
Other ophthalmology in Nashville
- Deborah ShermanNashville$3M
- Brian BiesmanNashville$630K
- Edward ChaumNashville$158K
- Jeffrey HornNashville$106K
- Avni FinnNashville$57K
- Louise MawnNashville$56K
- Jeffrey KammerNashville$30K
- Gary JerkinsNashville$15K
- Allison SmithNashville$13K
- Christine ShiehNashville$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.